Market closed
Axsome Therapeutics/$AXSM
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Axsome Therapeutics
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Ticker
$AXSM
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
607
Website
AXSM Metrics
BasicAdvanced
$4.7B
Market cap
-
P/E ratio
-$6.53
EPS
1.25
Beta
-
Dividend rate
Price and volume
Market cap
$4.7B
Beta
1.25
52-week high
$99.50
52-week low
$64.11
Average daily volume
532K
Financial strength
Current ratio
2.442
Quick ratio
2.301
Long term debt to equity
203.872
Total debt to equity
207.001
Interest coverage (TTM)
-48.58%
Management effectiveness
Return on assets (TTM)
-26.44%
Return on equity (TTM)
-171.61%
Valuation
Price to revenue (TTM)
13.75
Price to book
50.96
Price to tangible book (TTM)
146.32
Price to free cash flow (TTM)
-35.04
Growth
Revenue change (TTM)
51.47%
Earnings per share change (TTM)
43.92%
3-year earnings per share growth (CAGR)
24.97%
What the Analysts think about AXSM
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Axsome Therapeutics stock.
AXSM Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
AXSM Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
AXSM News
AllArticlesVideos
Axsome: Focus On AXS-12 Targeting Narcolepsy, Which Just Released Positive Data
Seeking Alpha·2 weeks ago
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says
Benzinga·2 weeks ago
Axsome Therapeutics, Inc. (AXSM) Q3 2024 Earnings Call Transcript
Seeking Alpha·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Axsome Therapeutics stock?
Axsome Therapeutics (AXSM) has a market cap of $4.7B as of December 13, 2024.
What is the P/E ratio for Axsome Therapeutics stock?
The price to earnings (P/E) ratio for Axsome Therapeutics (AXSM) stock is 0 as of December 13, 2024.
Does Axsome Therapeutics stock pay dividends?
No, Axsome Therapeutics (AXSM) stock does not pay dividends to its shareholders as of December 13, 2024.
When is the next Axsome Therapeutics dividend payment date?
Axsome Therapeutics (AXSM) stock does not pay dividends to its shareholders.
What is the beta indicator for Axsome Therapeutics?
Axsome Therapeutics (AXSM) has a beta rating of 1.25. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.